07:21 EDT Viking Therapeutics (VKTX) falls 29% to $29.60 after Phase 2 VK2735 test results
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735 achieves endpoints in Phase 2 obesity trial
- Viking Therapeutics’ VK2735: A Promising Contender in the Obesity Treatment Market
- Viking Therapeutics call volume above normal and directionally bullish
- BofA defends Eli Lilly following selloff on weight loss pill trial data
- Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating